Cargando…
Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care
OBJECTIVES: To study the impact of treatment strategy on achieving and sustaining disease-modifying antirheumatic drug (DMARD)-free remission in patients with rheumatoid arthritis (RA). METHODS: Two hundred seventy-nine RA patients (median follow-up 7.8 years) were studied. Of these, 155 patients pa...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505077/ https://www.ncbi.nlm.nih.gov/pubmed/31064384 http://dx.doi.org/10.1186/s13075-019-1893-z |
_version_ | 1783416684227330048 |
---|---|
author | Burgers, L. E. van der Pol, J. A. Huizinga, T. W. J. Allaart, C. F. van der Helm-van Mil, A. H. M. |
author_facet | Burgers, L. E. van der Pol, J. A. Huizinga, T. W. J. Allaart, C. F. van der Helm-van Mil, A. H. M. |
author_sort | Burgers, L. E. |
collection | PubMed |
description | OBJECTIVES: To study the impact of treatment strategy on achieving and sustaining disease-modifying antirheumatic drug (DMARD)-free remission in patients with rheumatoid arthritis (RA). METHODS: Two hundred seventy-nine RA patients (median follow-up 7.8 years) were studied. Of these, 155 patients participated in a disease activity score (DAS) < 1.6 steered trial aimed at DMARD-free remission. Initial treatment comprised methotrexate with high-dose prednisone (60 mg/day) and a possibility to start biologicals after 4 months. In the same period and hospital, 124 patients were treated according to routine care, comprising DAS < 2.4 steered treatment. Percentages of DMARD-free remission (absence of synovitis for ≥ 1 year after DMARD cessation), late flares (recurrence of clinical synovitis ≥ 1 year after DMARD cessation), and DMARD-free sustained remission (DMARD-free remission sustained during complete follow-up) were compared between both treatment strategies. RESULTS: Patients receiving intensive treatment were younger and more often ACPA-positive. On a group level, there was no significant association between intensive treatment and DMARD-free remission (35% vs 29%, corrected hazard ratio (HR) 1.4, 95%CI 0.9–2.2), nor in ACPA-negative RA (49% versus 44%). In ACPA-positive RA intensive treatment resulted in more DMARD-free remission (25% vs 6%, corrected HR 4.9, 95%CI 1.4–17). Intensive treatment was associated with more late flares (20% versus 8%, HR 2.3, 95%CI 0.6–8.3). Subsequently, there was no difference in DMARD-free sustained remission on a group level (28% versus 27%), nor in the ACPA-negative (43% versus 42%) or ACPA-positive stratum (17% versus 6%, corrected HR 3.1, 95%CI 0.9–11). CONCLUSIONS: Intensive treatment did not result in more DMARD-free sustained remission, compared to routine up-to-date care. The data showed a tendency towards an effect of intensive treatment in ACPA-positive RA; this needs further investigation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13075-019-1893-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6505077 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-65050772019-05-10 Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care Burgers, L. E. van der Pol, J. A. Huizinga, T. W. J. Allaart, C. F. van der Helm-van Mil, A. H. M. Arthritis Res Ther Research Article OBJECTIVES: To study the impact of treatment strategy on achieving and sustaining disease-modifying antirheumatic drug (DMARD)-free remission in patients with rheumatoid arthritis (RA). METHODS: Two hundred seventy-nine RA patients (median follow-up 7.8 years) were studied. Of these, 155 patients participated in a disease activity score (DAS) < 1.6 steered trial aimed at DMARD-free remission. Initial treatment comprised methotrexate with high-dose prednisone (60 mg/day) and a possibility to start biologicals after 4 months. In the same period and hospital, 124 patients were treated according to routine care, comprising DAS < 2.4 steered treatment. Percentages of DMARD-free remission (absence of synovitis for ≥ 1 year after DMARD cessation), late flares (recurrence of clinical synovitis ≥ 1 year after DMARD cessation), and DMARD-free sustained remission (DMARD-free remission sustained during complete follow-up) were compared between both treatment strategies. RESULTS: Patients receiving intensive treatment were younger and more often ACPA-positive. On a group level, there was no significant association between intensive treatment and DMARD-free remission (35% vs 29%, corrected hazard ratio (HR) 1.4, 95%CI 0.9–2.2), nor in ACPA-negative RA (49% versus 44%). In ACPA-positive RA intensive treatment resulted in more DMARD-free remission (25% vs 6%, corrected HR 4.9, 95%CI 1.4–17). Intensive treatment was associated with more late flares (20% versus 8%, HR 2.3, 95%CI 0.6–8.3). Subsequently, there was no difference in DMARD-free sustained remission on a group level (28% versus 27%), nor in the ACPA-negative (43% versus 42%) or ACPA-positive stratum (17% versus 6%, corrected HR 3.1, 95%CI 0.9–11). CONCLUSIONS: Intensive treatment did not result in more DMARD-free sustained remission, compared to routine up-to-date care. The data showed a tendency towards an effect of intensive treatment in ACPA-positive RA; this needs further investigation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13075-019-1893-z) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-07 2019 /pmc/articles/PMC6505077/ /pubmed/31064384 http://dx.doi.org/10.1186/s13075-019-1893-z Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Burgers, L. E. van der Pol, J. A. Huizinga, T. W. J. Allaart, C. F. van der Helm-van Mil, A. H. M. Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care |
title | Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care |
title_full | Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care |
title_fullStr | Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care |
title_full_unstemmed | Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care |
title_short | Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care |
title_sort | does treatment strategy influence the ability to achieve and sustain dmard-free remission in patients with ra? results of an observational study comparing an intensified das-steered treatment strategy with treat to target in routine care |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505077/ https://www.ncbi.nlm.nih.gov/pubmed/31064384 http://dx.doi.org/10.1186/s13075-019-1893-z |
work_keys_str_mv | AT burgersle doestreatmentstrategyinfluencetheabilitytoachieveandsustaindmardfreeremissioninpatientswithraresultsofanobservationalstudycomparinganintensifieddassteeredtreatmentstrategywithtreattotargetinroutinecare AT vanderpolja doestreatmentstrategyinfluencetheabilitytoachieveandsustaindmardfreeremissioninpatientswithraresultsofanobservationalstudycomparinganintensifieddassteeredtreatmentstrategywithtreattotargetinroutinecare AT huizingatwj doestreatmentstrategyinfluencetheabilitytoachieveandsustaindmardfreeremissioninpatientswithraresultsofanobservationalstudycomparinganintensifieddassteeredtreatmentstrategywithtreattotargetinroutinecare AT allaartcf doestreatmentstrategyinfluencetheabilitytoachieveandsustaindmardfreeremissioninpatientswithraresultsofanobservationalstudycomparinganintensifieddassteeredtreatmentstrategywithtreattotargetinroutinecare AT vanderhelmvanmilahm doestreatmentstrategyinfluencetheabilitytoachieveandsustaindmardfreeremissioninpatientswithraresultsofanobservationalstudycomparinganintensifieddassteeredtreatmentstrategywithtreattotargetinroutinecare |